Bluejay Investor Presentation Deck

Bluejay Overview Clinical Stage Diagnostic Company Developing the Symphony TM Product Pipeline Rapidly measuring levels of Interleukin-6 (IL-6) with our initial focus on sepsis triage and monitoring DO Novel Proprietary Platform ●●● 00 Symphony™ Product Lead Candidate: IL-6 Assay Market Opportunity Commercial Strategy $ Capital Efficient Model bluejay DIAGNOSTICS Uses whole blood (no pre-processing) Results in ~20 minutes Completed initial clinical studies for measuring IL-6 in critical care settings Conducting additional studies to support planned 510(k) FDA submission Symphony™ Product Pipeline addresses multi-billion-dollar market Near-patient testing (NPT) for monitoring of disease progression Sales model initially targets clinical sites and commercial partnerships Large, well-respected clinical sites are built-in commercial customers No debt, $5.1 M in cash as of June 30, 2023 The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 3

View entire presentation